REGENXBIO Inc. Common Stock (RGNX)

About RGNX

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabeti…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

371

Website

www.regenxbio.com

Fundamentals

1-day range

$10.34$10.86

Market cap

$514.91M

P/E (trailing)

—

P/E (forward)

-4.66

EPS (trailing)

$-3.78

Dividend yield

—

Beta

0.94

Avg. volume

2.03M

Forecasts

11 analyst ratings

REGENXBIO Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• RGNX

  REGENXBIO Inc. Common Stock

  $9.66

  ▲ 3.09%
  Market cap $514.91MP/E —
  $5.46$16.19
• PRME

  Prime Medicine Inc. Common Stock

  $3.62

  ▼ 0.69%
  Market cap $507.54MP/E —
  $2.67$6.94
• ZURA

  Zura Bio Limited Class A Ordinary Shares

  $5.73

  ▼ 2.05%
  Market cap $524.39MP/E —
  $1.88$7.44
• TECX

  Tectonic Therapeutic Inc. Common Stock

  $35.69

  ▼ 2.75%
  Market cap $526.83MP/E —
  $14.39$39.53
• FDMT

  4D Molecular Therapeutics Inc. Common Stock

  $14.65

  ▼ 1.74%
  Market cap $527.47MP/E —
  $5.97$16.93
• VALN

  Valneva SE American Depositary Shares

  $6.43

  ▼ 2.13%
  Market cap $491.51MP/E —
  $2.03$5.34
• DNA

  Ginkgo Bioworks Holdings Inc. Class A Common Stock

  $6.98

  ▼ 3.93%
  Market cap $555.49MP/E —
  $5.37$17.58

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade)
  SeekingAlpha · 8/11/2026
• This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
  Benzinga · 8/10/2026
• HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $23
  Benzinga · 8/10/2026
• This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday
  Benzinga · 8/7/2026
• REGENXBIO Q2 Earnings Call Highlights
  Yahoo · 8/7/2026
• This HubSpot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
  Benzinga · 8/7/2026
• Barclays Downgrades Regenxbio to Equal-Weight, Maintains Price Target to $12
  Benzinga · 8/7/2026
• Regenxbio Inc (RGNX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended into Q4 2027 on ...
  Yahoo · 8/6/2026

• Steve Pakola · August 1, 2026 · Tax Withholding

  7.5K @ $9.69
• Patrick J. Christmas · August 1, 2026 · Tax Withholding

  4.7K @ $9.69
• Steve Pakola · July 2, 2026 · Option Exercise

  2.2K @ $7.86
• Steve Pakola · July 2, 2026 · Sale

  2.2K @ $13.64
• Steve Pakola · July 1, 2026 · Option Exercise

  36.7K @ $7.86
• Steve Pakola · July 1, 2026 · Sale

  36.7K @ $12.86
• Curran Simpson · July 1, 2026 · Tax Withholding

  6.8K @ $13.09
• Curran Simpson · June 30, 2026 · Grant

  1.5K @ $10.18
• Steve Pakola · June 29, 2026 · Sale

  19.6K @ $11.04
• Jean Bennett · May 29, 2026 · Grant

  46.6K
• Jean Bennett · May 29, 2026 · Grant

  9.8K
• Jennifer Zachary · May 29, 2026 · Grant

  46.6K
• Jennifer Zachary · May 29, 2026 · Grant

  9.8K
• Alexandra Glucksmann · May 29, 2026 · Grant

  46.6K
• Alexandra Glucksmann · May 29, 2026 · Grant

  9.8K

Institutional Ownership

March 31, 2026

Total shares held

38.31M

Total value held

$316.23M

Institutional holders

172